{
   "source_x": "PMC",
   "title": "Clinicopathologic Implications of Eukaryotic Initiation Factor 3f and Her\u20102/neu Expression in Gastric Cancer",
   "doi": "http://dx.doi.org/10.1111/cts.12263",
   "pmcid": "PMC5351038",
   "abstract": "BACKGROUND: To detect the expression of eIF3f and human epidermal growth factor receptor 2 (Her\u20102)/neu in gastric cancer (GC), correlation with their clinicopathological parameters and the relationship of eIF3f and Her\u20102/neu in the occurrence and development of GC. METHODS: A total of 195 gastrectomy specimens with stage I to III were examined for eIF3f expression by immunohistochemistry and for Her\u20102/neu expression by fluorescence in situ hybridization (FISH) with the median follow\u2010up period of 38 months. RESULTS: The positive expression rate of eIF3f in GC and adjacent noncancerous tissue were 33.8% and 59.5%, respectively. eIF3f levels were linked to more advanced tumor stages and likelihood of recurrence (all p < 0.05). The Kaplan\u2013Meier survival curves indicated that decreased expression of eIF3f could serve as a prognosis marker for poor outcome of GC patients (p = 0.04). 15.9% of GC specimens were positive for Her\u20102/neu, but whose expression was of no correlation with patients\u2019 survival. Patients who were positive for Her\u20102/neu also had high eIF3f expression levels (p = 0.0295). CONCLUSION: Results suggest that eIF3f may play an important role in recurrence, thus representing a promising predictive marker for the prognosis of GC. But Her\u20102/neu has no relationship with the prognosis of GC. The clinical significance of eIF3f and Her\u20102/neu remains to be further investigated.",
   "authors": [
      "['Cheng, Yu', 'Zhou, Jin', 'Li, Honglun']"
   ],
   "id": "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5351038"
}